Johnson & Johnson (JNJ) Announces TREMFYA Sustains Outcomes in Ulcerative Colitis Study

Johnson & Johnson announced on February 21, 2026, that TREMFYA (guselkumab) sustained clinical, endoscopic, and histologic outcomes in patients with moderately to severely active ulcerative colitis through one year of treatment. The data reinforces the drug’s potential for label expansion into the inflammatory bowel disease market. Results from the Phase 3 maintenance study demonstrated durable remission rates across multiple efficacy endpoints. TREMFYA, an IL-23 inhibitor currently approved for psoriatic arthritis and plaque psoriasis, serves as a key growth driver for the company. Successful approval for ulcerative colitis would position the therapy against competitors like AbbVie’s Skyrizi in the competitive gastroenterology sector.